Skip to content Skip to footer
Subscribe Now
Exclusive_Stacey Williams_2023
EXCLUSIVE

Stacey Williams, Vice President, Marketing, Dermavant Shares Insights on New Campaigns for Adults with Plaque Psoriasis

Shots: Stacey talked about the launch of its first streaming commercial as part of a direct-to-consumer advertising campaign for adults with plaque psoriasis The “Topical Uprising” campaign focuses on the patient journey and taps into the frustrations & self-conscious of living with plaque psoriasis that helps patients to demand more from their topical plaque psoriasis treatment The…
January 23, 2023

Read more

thoughtspot_Jenny Blake
THOUGHTSPOT

Pharmacy In The Era Of Telehealth

Telehealth has become a reality in modern times. The new era of telehealth offers numerous benefits for patients and healthcare professionals alike. With this new era becoming normal in our lives, pharmacists have a significant role to play. They are key players in setting up telemedicine in healthcare and ensuring patients understand this advancement. This guide will…
January 17, 2023

Read more

VIEWPOINTS_Dr. Richard Philipson_2023
VIEWPOINTS

Dr. Richard Philipson, CMO at Calliditas Shares Results & Insights from P-III Study Evaluating Tarpeyo

Shots:  Dr. Richard talked about the results from the NefIgArd P-III trial evaluating Tarpeyo (Nefecon) for the treatment of IgA Nephropathy  He also highlighted the safety and efficacy results from the NefIgArd study. He also spoke more about Trapeyo and the roadmap for its global approval and commercialization  The interview shows up how Calliditas is…
January 9, 2023

Read more

VIEWPOINTS_Dr. Jeff Cleland_2023
VIEWPOINTS

Dr. Jeff Cleland, CEO & President at Ashvattha Therapeutics Shares his Views From First Patient Enrolled for the Treatment of AMD and DME

Shots: Jeff spoke about the first patient enrolled in a P-II study of D-4517.2 for the treatment of wet AMD and DME Jeff also talked about Ashvatta’s Hydroxyl Dendrimer Platform and how this technology is beneficial to treat AMD and DME The interview gives a profound understanding of how Ashvattha is developing hydroxyl dendrimer therapeutics…
January 3, 2023

Read more

Load more